CRYOPORT, INC. Amortization of Debt Issuance Costs
CRYOPORT, INC. (CYRX) reported Amortization of Debt Issuance Costs of $2.53 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2024-03-13
- CRYOPORT, INC. amortization of debt issuance costs for the quarter ending 2023-06-30 was $643.00K, a 1.42% increase year-over-year.
- CRYOPORT, INC. amortization of debt issuance costs for the quarter ending 2023-03-31 was $641.00K, a 1.58% increase year-over-year.
- CRYOPORT, INC. amortization of debt issuance costs for the quarter ending 2022-12-31 was $634.00K, a 77.68% decline year-over-year.
- CRYOPORT, INC. amortization of debt issuance costs for the quarter ending 2022-09-30 was $635.00K, a 227.32% increase year-over-year.
- CRYOPORT, INC. amortization of debt issuance costs for fiscal 2023 was $2.53M, a 0.43% decline from fiscal 2022.
- CRYOPORT, INC. amortization of debt issuance costs for fiscal 2022 was $2.54M, a 25.80% decline from fiscal 2021.
- CRYOPORT, INC. amortization of debt issuance costs for fiscal 2021 was $3.42M, a 682.38% increase from fiscal 2020.
- CRYOPORT, INC. amortization of debt issuance costs for fiscal 2020 was $437.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 3 month as first filed | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $2.53M 10-K · filed 2024-03-13 | ||||
| 2023-06-30 | $643.00K 10-Q · filed 2023-08-09 | $1.28M 10-Q · filed 2023-08-09 | $1.92M derived: sum of 3 quarters · filed 2024-03-13 | $2.55M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-03-31 | $641.00K 10-Q · filed 2023-05-04 | $1.27M derived: sum of 2 quarters · filed 2024-03-13 | $1.91M derived: sum of 3 quarters · filed 2024-03-13 | $2.54M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-12-31 | $634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.27M derived: sum of 2 quarters · filed 2024-03-13 | $1.90M derived: sum of 3 quarters · filed 2024-03-13 | $2.54M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $635.00K 10-Q · filed 2022-11-04 | $1.27M derived: sum of 2 quarters · filed 2023-08-09 | $1.90M 10-Q · filed 2022-11-04 | $4.74M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-06-30 | $634.00K 10-Q · filed 2023-08-09 | $1.27M 10-Q · filed 2023-08-09 | $4.11M derived: sum of 3 quarters · filed 2024-03-13 | $4.30M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-03-31 | $631.00K 10-Q · filed 2023-05-04 | $3.47M derived: sum of 2 quarters · filed 2024-03-13 | $3.67M derived: sum of 3 quarters · filed 2024-03-13 | $3.86M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2021-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $3.03M derived: sum of 2 quarters · filed 2024-03-13 | $3.23M derived: sum of 3 quarters · filed 2024-03-13 | $3.42M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $194.00K 10-Q · filed 2022-11-04 | $387.00K derived: sum of 2 quarters · filed 2022-11-04 | $579.00K 10-Q · filed 2022-11-04 | $768.40K derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $193.00K 10-Q · filed 2022-08-04 | $385.00K 10-Q · filed 2022-08-04 | $574.40K derived: sum of 3 quarters · filed 2023-02-28 | $766.40K derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $192.00K 10-Q · filed 2022-05-05 | $381.40K derived: sum of 2 quarters · filed 2023-02-28 | $573.40K derived: sum of 3 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $189.40K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $381.40K derived: sum of 2 quarters · filed 2023-02-28 | $437.00K 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $192.00K 10-Q · filed 2021-05-06 | $187.50K 10-Q · filed 2020-11-06 | $247.60K 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $60.10K 10-Q · filed 2020-08-10 | ||||
| 2013-12-31 | $41.89K 10-Q · filed 2014-02-13 | ||||
| 2013-03-31 | $8.67K 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |